In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 9, 2012, Pages 2195-2202

  Spreghini, Elisabetta ^a   Orlando, Fiorenza ^b   Tavanti, Arianna ^c   Senesi, Sonia ^c   Giannini, Daniele ^a   Manso, Esther ^d   Barchiesi, Francesco ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d OSPEDALI RIUNITI   (Italy)

Author keywords

Anidulafungin; Candida parapsilosis complex species; Candidiasis; Caspofungin; Micafungin

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; CASPOFUNGIN; MICAFUNGIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD SAMPLING; BROTH DILUTION; CANDIDA; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS SENSU STRICTO; CONTROLLED STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INVASIVE CANDIDIASIS; KIDNEY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; TREATMENT DURATION;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; ECHINOCANDINS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; KIDNEY; MICE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; TREATMENT OUTCOME;

EID: 84865378162     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks180     Document Type: Article

References (28)

1. Bassetti M, Taramasso L, Nicco E et al. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One 2011; 6: e24198.
2. Lockhart SR, Messer SA, Pfaller MA et al. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol 2008; 46: 2659-64.
3. Pfaller MA, Diekema DJ, Gibbs DL et al. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008; 46: 842-9.
4. Brito LR, Guimarães T, Nucci M et al. Clinical and microbiological aspects of candidemia due to Candida parapsilosis in Brazilian tertiary care hospitals. Med Mycol 2006; 44: 261-6.
5. Enger L, Joly S, Pujol C et al. Cloning and characterization of a complex DNA fingerprinting probe for Candida parapsilosis. J Clin Microbiol 2001; 39: 658-69.
6. Lin D, Wu LC, Rinaldi MG et al. Three distinct genotypes within Candida parapsilosis from clinical sources. J Clin Microbiol 1995; 33: 1815-21.
7. Lott TJ, Kuykendall RJ, Welbel SF et al. Genomic heterogeneity in the yeast Candida parapsilosis. Curr Genet 1993; 23: 463-7.
8. Tavanti A, Hensgens LA, Ghelardi E et al. Genotyping of Candida orthopsilosis clinical isolates by amplification fragment length polymorphism reveals genetic diversity among independent isolates and strain maintenance within patients. J Clin Microbiol 2007; 45: 1455-62.
9. Tavanti A, Davidson AD, Gow NA et al. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005; 43: 284-92.
10. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008; 46: 2620-9.
11. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Third Edition: Approved Standard M27-A3. CLSI, Wayne, PA, USA, 2008.
12. Paderu P, Garcia-Effron G, Balashov S et al. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 2007; 51: 2253-6.
13. Miranda-Zapico I, Eraso E, Hernández-Almaraz JL et al. Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital. J Antimicrob Chemother 2011; 66: 2315-22.
14. Cantón E, Pemán J, Quindós G et al. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother 2011; 55: 5590-6.
15. Diekema DJ, Messer SA, Boyken LB et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol 2009; 47: 3170-7.
16. Gomez-Lopez A, Alastruey-Izquierdo A, Rodriguez D et al. Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother 2008; 52: 1506-9.
17. Varga I, Sóczó G, Kardos G et al. Comparison of killing activity of caspofungin against Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis. J Antimicrob Chemother 2008; 62: 1466-8.
18. Pfaller MA, Diekema DJ, Andes D et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14: 164-76.
19. Ishikawa J, Maeda T, Matsumura I et al. Antifungal activity of micafungin in serum. Antimicrob Agents Chemother 2009; 53: 4559-62.
20. Odabasi Z, Paetznick V, Rex JH et al. Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob Agents Chemother 2007; 51: 4214-6.
21. Garcia-Effron G, Park S, Perlin DS. Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin. Antimicrob Agents Chemother 2011; 55: 2245-55.
22. Arendrup MC, Rodriguez-Tudela JL, Park S et al. Echinocandin susceptibility testing of Candida spp. using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob Agents Chemother 2011; 55: 1580-7.
23. Espinel-Ingroff A, Cantón E. In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same? Enferm Infecc Microbiol Clin 2011; 29 Suppl 2: 3-9.
24. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 121-36.
25. Cantón E, Espinel-Ingroff A, Pemán J et al. In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. Antimicrob Agents Chemother 2010; 54: 2194-7.
26. Salas V, Pastor FJ, Calvo E et al. Anidulafungin in treatment of experimental invasive infection by Candida parapsilosis: in vitro activity, (1_3)-b-D-glucan and mannan serum levels, histopathological findings, and in vivo efficacy. Antimicrob Agents Chemother 2011; 55: 4985-9.
27. Andes D, Diekema DJ, Pfaller MA et al. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 2010; 54: 2497-506.
28. Garcia-Effron G, Katiyar SK, Park S et al. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008; 52: 2305-12.